Gold prices edge higher on raised Fed rate cut hopes
Introduction & Market Context
Arcutis Biotherapeutics (NASDAQ:ARQT) presented its first quarter 2025 financial results on May 6, highlighting substantial year-over-year growth despite typical seasonal challenges. The dermatology-focused biopharmaceutical company continues to expand its ZORYVE portfolio across multiple inflammatory skin conditions in a market dominated by topical steroids.
The company operates in a substantial addressable market of approximately 17 million patients across psoriasis, seborrheic dermatitis, and atopic dermatitis. While steroids still command 69% of the topical treatment market, Arcutis is positioning itself as a leader in the growing branded non-steroidal segment, which currently represents 17% of prescriptions.
As shown in the following market opportunity breakdown:
Quarterly Performance Highlights
Arcutis reported Q1 2025 net product revenue of $63.8 million, representing a 196% increase compared to the same period last year. However, revenue declined slightly from the $65.3 million reported in Q4 2024, which the company attributed to typical first-quarter gross-to-net (GTN) erosion due to annual deductible and insurance resets.
The following chart illustrates the company’s revenue trajectory over recent quarters:
Total (EPA:TTEF) prescriptions (TRx) for the ZORYVE portfolio continued to show strong momentum, with 10% growth compared to Q4 2024 and an impressive 169% increase year-over-year. This prescription growth demonstrates increasing physician adoption across multiple indications.
The prescription growth trend is clearly visible in this chart:
Commercial and Market Position
Arcutis has positioned ZORYVE as the #1 prescribed topical for three major inflammatory skin conditions: plaque psoriasis, seborrheic dermatitis, and atopic dermatitis. The company’s strategy focuses on converting patients from topical steroids to its non-steroidal alternatives.
The branded topical segment grew by 50% from Q1 2024 to Q1 2025, with ZORYVE capturing an increasing share within this growing market. Arcutis is competing with other non-steroidal options like Opzelura, VTAMA, and Eucrisa, but has shown stronger prescription growth.
This chart demonstrates the growth of the branded topical segment and ZORYVE’s expanding market share:
A key strength for Arcutis is its diverse portfolio of formulations and concentrations tailored to specific conditions and body areas. The company offers ZORYVE 0.3% in both cream and foam formulations for plaque psoriasis and seborrheic dermatitis, and ZORYVE 0.15% cream for atopic dermatitis.
The company has achieved robust payor coverage, with approximately 80% of prescriptions covered across all formulations. This strong reimbursement profile supports continued commercial momentum.
Pipeline and R&D Progress
Arcutis continues to advance its clinical and regulatory milestones. The company has an upcoming PDUFA target action date of May 22, 2025, for ZORYVE Foam 0.3% for scalp and body psoriasis in patients aged 12 and older. Additionally, Arcutis has submitted a supplemental New Drug Application (sNDA) for ZORYVE Cream 0.05% for atopic dermatitis in children ages 2-5, with an anticipated target action date of October 13, 2025.
The company’s R&D pipeline includes several other developments, as outlined in this comprehensive milestone chart:
Clinical evidence continues to support the efficacy of Arcutis’ products. The company presented compelling before-and-after images of patients treated with ZORYVE Foam 0.3%, showing significant improvement in psoriasis symptoms over an eight-week treatment period:
Arcutis is also benefiting from a growing consensus within the dermatology community regarding the need to shift away from long-term steroid use. The company highlighted recent publications in dermatology journals that support this trend, strengthening the market positioning of ZORYVE as a non-steroidal alternative.
Financial Results and Outlook
For Q1 2025, Arcutis reported total revenues of $65.8 million, compared to $49.6 million in Q1 2024. The company’s net loss improved to $25.1 million, or $0.20 per share, compared to a net loss of $35.4 million, or $0.32 per share, in the prior-year period.
The detailed financial results are presented in this table:
Arcutis maintained a strong cash position of $198.7 million in cash, cash equivalents, and marketable securities as of March 31, 2025. Net cash used in operating activities was $30.4 million for the quarter. The company also noted that it has $100 million of debt available through its current loan facility, accessible in whole or in part by June 2026.
Looking ahead, Arcutis expects sustained volume and revenue growth throughout 2025, driven by increasing prescription demand across its expanding portfolio. The company’s strategy of targeting healthcare providers who prescribe across multiple indications appears to be paying dividends, with data showing that three-indication writers prescribe approximately 31 prescriptions per healthcare provider over a 13-week period, compared to just 3 prescriptions for single-indication writers.
In the broader market context, Arcutis stock closed at $14.34 on May 6, 2025, down 6.96% from the previous close of $15.41. The stock has traded between $6.99 and $17.75 over the past 52 weeks, indicating significant volatility despite the company’s continued revenue growth.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.